G
162.96
0.88 (0.54%)
| Previous Close | 162.09 |
| Open | 159.89 |
| Volume | 390,469 |
| Avg. Volume (3M) | 1,969,431 |
| Market Cap | 21,868,607,488 |
| Price / Sales | 19.38 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.88 |
Select this tab to load the latest available analysis.
|
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BELL MICHAEL BRIAN | - | 174.75 | -3,914 | -683,972 |
| CHUDOVA DARYA | - | 174.75 | -4,320 | -754,920 |
| ELTOUKHY HELMY | - | 176.56 | -18,515 | -3,240,651 |
| FREEMAN CHRIS | - | 174.75 | -3,143 | -549,239 |
| KALIA KUMUD | - | 174.75 | -3,067 | -535,958 |
| MONROE TERILYN J. | - | 174.75 | -2,098 | -366,626 |
| SAIA JOHN G. | - | 174.75 | -3,706 | -647,624 |
| TALASAZ AMIRALI | - | 176.56 | -18,515 | -3,240,651 |
| Aggregate Net Quantity | -57,278 | |||
| Aggregate Net Value ($) | -10,019,641 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 175.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ELTOUKHY HELMY | Officer | 01 Oct 2026 | Disposed (-) | 17,087 | 174.75 | 2,985,953 |
| ELTOUKHY HELMY | Officer | 01 Oct 2026 | Option execute | 33,713 | - | - |
| TALASAZ AMIRALI | Officer | 01 Oct 2026 | Disposed (-) | 17,087 | 174.75 | 2,985,953 |
| TALASAZ AMIRALI | Officer | 01 Oct 2026 | Option execute | 33,713 | - | - |
| BELL MICHAEL BRIAN | Officer | 01 Oct 2026 | Disposed (-) | 3,914 | 174.75 | 683,972 |
| BELL MICHAEL BRIAN | Officer | 01 Oct 2026 | Option execute | 7,280 | - | - |
| CHUDOVA DARYA | Officer | 01 Oct 2026 | Disposed (-) | 4,320 | 174.75 | 754,920 |
| CHUDOVA DARYA | Officer | 01 Oct 2026 | Option execute | 8,033 | - | - |
| FREEMAN CHRIS | Officer | 01 Oct 2026 | Disposed (-) | 3,143 | 174.75 | 549,239 |
| FREEMAN CHRIS | Officer | 01 Oct 2026 | Option execute | 7,416 | - | - |
| KALIA KUMUD | Officer | 01 Oct 2026 | Disposed (-) | 3,067 | 174.75 | 535,958 |
| KALIA KUMUD | Officer | 01 Oct 2026 | Option execute | 6,046 | - | - |
| MONROE TERILYN J. | Officer | 01 Oct 2026 | Disposed (-) | 2,098 | 174.75 | 366,626 |
| MONROE TERILYN J. | Officer | 01 Oct 2026 | Option execute | 4,019 | - | - |
| SAIA JOHN G. | Officer | 01 Oct 2026 | Disposed (-) | 3,706 | 174.75 | 647,624 |
| SAIA JOHN G. | Officer | 01 Oct 2026 | Option execute | 7,063 | - | - |
| ELTOUKHY HELMY | Officer | 30 Sep 2026 | Disposed (-) | 1,428 | 178.36 | 254,698 |
| ELTOUKHY HELMY | Officer | 30 Sep 2026 | Option execute | 2,817 | - | - |
| TALASAZ AMIRALI | Officer | 30 Sep 2026 | Disposed (-) | 1,428 | 178.36 | 254,698 |
| TALASAZ AMIRALI | Officer | 30 Sep 2026 | Option execute | 2,817 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |